We’re thrilled to announce that the winner of the 2024 Statistical Excellence in the Pharmaceutical Industry Award is the GSK Biostatistics team for their entry ‘Successful Use of Bayesian Dynamic Borrowing Methods in Regulatory Settings’.
The GSK Biostatistics team has successfully used Bayesian Dynamic Borrowing (BDB) in a commercial setting, which allows for the re-use of external data, synthesising new and existing data to increase efficiency whilst maintaining rigorous standards for regulatory decision making.
The judging panel was impressed by the culmination of years of work invested in this project – starting with the development and publication of innovative methodology, followed by diligent efforts to communicate this methodology to regulators and stakeholders. The acceptance of Bayesian approaches by regulators is a big step forward, widely acknowledged within the industry and beyond.
The award presentation took place at the PSI annual conference in Amsterdam, where Nicky Best and Andrea Callegaro collected the
award on behalf of the Biostatistics team.
RSS CEO Sarah Cumbers said, ‘A well-deserved congratulations go to the team at GSK. The inclusion of Bayesian Dynamic Borrowing in recent examples of regulatory decisions represents a paradigm shift that is a huge step forward in the pharmaceutical industry’.
David Wright, chair of PSI said, ‘Many congratulations to Nicky Best, Andrea Callegaro, Brigitte Cheuvart, Cui Xiong, Dawn Edwards and Jodie Crawford for their work on commercialization of Bayesian Dynamic Borrowing. It is a significant achievement and well-deserved recognition for their statistical excellence in the pharmaceutical industry.’